SECOND LINE ERLOTINIB IN NON-SMALL CELL LUNG CANCER: A LOCAL EXPERIENCE

被引：0
|
作者：
Smith, C. F. [1 ]
Garcia-Alonso, Angel [1 ]
Drury, G. [1 ]
Gostage, A. [1 ]
Smith, N. [1 ]
机构：
[1] Betsi Cadwaladr Univ Hlth Board, N Wales Canc Treatment Ctr, Bangor, Gwynedd, Wales
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
erlotinib; second line; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S1180 / S1181
页数：2
相关论文
共 50 条
  • [21] Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)
    Kayali, F.
    Janjua, M. A.
    Laber, D. A.
    Miller, D. M.
    Day, J. M.
    Kloecker, G. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] COST COMPARISON OF ERLOTINIB VERSUS GENERIC DOCETAXEL IN SECOND-LINE NON-SMALL CELL LUNG CANCER IN ITALY
    Schwander, B.
    Ravera, S.
    Giuliani, G.
    Nuijten, M.
    Walzer, S.
    VALUE IN HEALTH, 2012, 15 (04) : A214 - A214
  • [23] Reviewing the safety of erlotinib in non-small cell lung cancer
    Reck, Martin
    Mok, Tony
    Wolf, Juergen
    Heigener, David
    Wu, Yi-long
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) : 147 - 157
  • [24] Erlotinib for the treatment of relapsed non-small cell lung cancer
    McLeod, C.
    Bagust, A.
    Boland, A.
    Hockenhull, J.
    Dundar, Y.
    Proudlove, C.
    Davis, H.
    Green, J.
    Macbeth, F.
    Stevenson, J.
    Walley, T.
    Dickson, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 41 - 47
  • [25] Erlotinib (Tarceva) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1205): : 25 - 26
  • [26] Second line pembrolizumab for advanced non-small cell lung cancer: experience at University Hospital Waterford
    Farooq, A. R.
    Athanasiyar, V.
    Bracken-Clarke, D.
    Prior, L.
    Senanayeke, S.
    Horgan, A.
    Calvert, P.
    LUNG CANCER, 2018, 115 : S37 - S38
  • [27] Erlotinib for metastatic non-small cell lung cancer (mNSCLC): First, second or third line setting-Does it matter? A single institution experience
    Ailawadhi, S.
    Derby, L.
    Natrajan, R.
    Reid, M. E.
    Ramnath, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer
    Durm, Greg
    Hanna, Nasser
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 71 - +
  • [29] The use of second line docetaxel and nintedanib for non-small cell lung cancer
    Wasim, Z.
    Chowdhury, S.
    LUNG CANCER, 2018, 115 : S31 - S31
  • [30] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Cullen, M.
    LUNG CANCER, 2009, 64 : S13 - S13
12345